---
title: "Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295963071.md"
description: "LifeSci Capital reiterated a Buy rating on Pyxis Oncology with a $6 price target, citing MICVO's differentiated clinical profile and upcoming data catalysts in late 2025 and 2026. Wells Fargo also maintained a Buy rating with a higher $12 target."
datetime: "2026-08-14T17:05:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295963071.md)
  - [en](https://longbridge.com/en/news/295963071.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295963071.md)
generator: "portal-rs"
---

# Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology, with a price target of $6.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Sam Slutsky has given his Buy rating due to a combination of factors that center on MICVO’s differentiated clinical profile and upcoming data catalysts. The December 2025 results in heavily pretreated HNSCC patients showed a notably high response rate and disease control, supporting the drug’s antitumor activity despite safety challenges at the prior dosing strategy.

The decision to implement dose capping, backed by pharmacokinetic modeling, is designed to lower exposure in higher‑weight patients and potentially improve tolerability while preserving efficacy, making the forthcoming Fall 2026 monotherapy update a critical inflection point. Additional data from the MICVO–pembrolizumab combination in first‑line HNSCC, expected in Q4 2026, provides a second major catalyst, and Slutsky believes these events justify maintaining a $6 price target and a Buy rating despite the company’s limited cash runway.

In another report released today, Wells Fargo also reiterated a Buy rating on the stock with a $12.00 price target.

### Related Stocks

- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer](https://longbridge.com/en/news/295788544.md)
- [Canaccord Genuity Reaffirms Their Buy Rating on Labyrinth Resources Limited (GG8)](https://longbridge.com/en/news/296216069.md)
- [What Are Wall Street Analysts' Target Price for Expeditors International Stock?](https://longbridge.com/en/news/296206707.md)
- [Morgans Keeps Their Buy Rating on IRESS Limited (BRF)](https://longbridge.com/en/news/296168581.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**